Trend of A-share and Hong Kong stock innovative drug sector this week
In the fifth week of March 2022, a total of 15 stocks in the innovative drug sector in mainland and Hong Kong rose and 37 stocks fell. Among them, the top three were tengshengbo pharmaceutical-b (+ 13.2%), Hualing pharmaceutical-b (+ 10.03%) and Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (+ 9.03%). The top three declines were Rongchang bio-b (- 17%), Maibo pharmaceutical-b (- 15.56%) and Hansen Pharmaceutical (- 15.38%). This week, the A-share innovative drug sector rose 1.94%, underperforming the CSI 300 index by 2.43pp, and biomedicine rose 0.33%. In the past six months, A-share innovative drugs have fallen by 13.62%, underperforming the CSI 300 index by 12.51pp, and biomedicine has fallen by 18.05%. This week, the innovative drug sector of Hong Kong stocks fell 6.38%, underperforming the Hang Seng Index by 2.97pp, and Hang Seng healthcare rose 0.08%. Over the past six months, innovative drugs in Hong Kong stocks have fallen by 22.34%, underperforming the Hang Seng Index by 14.61pp, and Hang Seng health care has fallen by 33.28%. Progress of key innovative drugs in China
In March, a total of 10 new drugs were approved for marketing in China. This week, no drugs were approved for listing in China, and no innovative drugs were approved for new indications.
Progress of overseas key innovative drugs
In March, 13 new drugs were approved by FDA. This week, three new drugs were approved, namely, testerone undecanoate of antarespharma Inc., dolutegravir lamivudine of Cipla USA Inc., and abacavir dolutegravir lamivudine of vivhlthcare. In March, a new drug was approved for listing in Europe. This week, a new drug was approved, azd8895 + azd1061 of AstraZeneca ab.
In March, a total of 11 new drugs were approved for listing in Japan, and 8 new drugs were approved this week.
This week’s small topic – research and development progress of SGLT2 target
There are 57 SGLT2 inhibitors under development in the world, including 20 approved for listing, 1 applied for listing, 3 phase III clinical, 8 phase II clinical, 1 phase I / II clinical and 16 phase I clinical. There are 14 in research in China, including 1 approved for listing ( Jiangsu Hengrui Medicine Co.Ltd(600276) ), 3 in phase III clinical, 1 in phase I / II clinical and 6 in phase I clinical. These SGLT2 projects are monoclonal antibody projects without bispecific antibody or multispecific antibody projects.
Progress of global key innovative drug transactions this week
This week, there were 13 key transactions in the world, and there were 4 key transactions with disclosed amount, involving companies including igmbiosciences and Sanofi, numab therapeutics and Ono pharmaceutical, boaoxin biology and pyxis oncology, Dar é Bioscience and organon.
Risk warning: drug price reduction risk; The implementation progress of medical reform policy is lower than the expected risk; Risk of R & D failure
